Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    +1.76 (+2.16%)
     
  • Gold

    2,254.80
    +42.10 (+1.90%)
     
  • Silver

    25.10
    +0.35 (+1.41%)
     
  • EUR/USD

    1.0792
    -0.0037 (-0.35%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2625
    -0.0013 (-0.10%)
     
  • USD/JPY

    151.3640
    +0.1180 (+0.08%)
     
  • Bitcoin USD

    70,816.64
    +1,718.73 (+2.49%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Aptiv (APTV) Beats Q3 Earnings and Revenue Estimates

Aptiv PLC APTV reported third-quarter 2018 (ended Sep 30, 2018) earnings per share of $1.24 (on an adjusted basis), beating the Zacks Consensus Estimate of $1.20.

How Was the Estimate Revision Trend?

Investors should note that the earnings estimate revisions for Aptiv depicted a pessimistic picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for third-quarter 2018 earnings move down 3.2% over the last 60 days.

However, the company has an impressive earnings history having outperformed the Zacks Consensus Estimate in three of the last four quarters with an average beat of 3.1%.

Revenues Higher Than Expected

Aptiv recorded total revenues of $3.5 billion which outperformed the Zacks Consensus Estimate of $3.4 billion.

Key Stats to Note: Aptiv trimmed its 2018 guidance.The company anticipates earnings to be in the range of $5.11 - $5.17 per share compared with the prior guidance of $5.30-$5.40 per share. Net sales are expected between $14.275 billion and $14.375 billion compared with $14.350 billion and $14.550 billion anticipated earlier.

Aptiv PLC Price

Aptiv PLC Price | Aptiv PLC Quote

Zacks Rank: Currently, Aptiv has a Zacks Rank #3 (Hold) but that could change following the company’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.  

Check back later for our full write up on this Aptiv earnings report later!

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Aptiv PLC (APTV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement